Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

BACKGROUND: Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. METHODS: In the Adjuvant Lapatinib a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Piccart-Gebhart, Martine, Holmes, Eileen, Baselga, José, de Azambuja, Evandro, Dueck, Amylou C., Viale, Giuseppe, Zujewski, Jo Anne, Goldhirsch, Aron, Armour, Alison, Pritchard, Kathleen I., McCullough, Ann E., Dolci, Stella, McFadden, Eleanor, Holmes, Andrew P., Tonghua, Liu, Eidtmann, Holger, Dinh, Phuong, Di Cosimo, Serena, Harbeck, Nadia, Tjulandin, Sergei, Im, Young-Hyuck, Huang, Chiun-Sheng, Diéras, Véronique, Hillman, David W., Wolff, Antonio C., Jackisch, Christian, Lang, Istvan, Untch, Michael, Smith, Ian, Boyle, Frances, Xu, Binghe, Gomez, Henry, Suter, Thomas, Gelber, Richard D., Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872016/
https://ncbi.nlm.nih.gov/pubmed/26598744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1797
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares